-
ALSO READ
Granules India receives EIR report for Granules Pharmaceuticals Inc. facility in Virginia Panacea Biotec receives EIR Report for its Oncology Parenteral Formulations manufacturing facility J B Chemicals gains after EU approval for mfg facilities at Panoli Granules India nudges higher after USFDA clears foreign subsidiary Aurobindo Pharma slides after clarification -
Receives one 483 observation for Jeedimetla facility
Granules India announced that the USFDA completed inspection of its Gagillapur facility without any 483 observation while it received 1 observation for Jeedimetla facility. The inspection at the two facilities was conducted from 19 March to 23 March 2018.Gagillapur facility manufactures finished dosage and pharmaceutical formulation intermediates whereas Jeedimetla facility manufactures active pharmaceutical ingredients and pharmaceuticals formulations intermediates.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
RECOMMENDED FOR YOU